Bioactive pea protein hydrolysate: pilot plant scale-up and beverage formulation (Phase 1)

我们之前的工作是从加拿大种植的黄豆种子中分离出一种具有生物活性的豌豆蛋白水解物(PPH)。口服给自发性高血压大鼠和人类受试者的收缩压分别降低了20和10毫米汞柱。基于动物和人体的研究，我们认为PPH是一种潜在的治疗高血压的药物。为了推动PPH走向成功的商业化，我们需要证明它可以大规模生产，适合向行业转移技术。此外，由于食品蛋白水解物的潜在苦味，我们必须证明，在不降低产品功效或效力的情况下，可以优化将产品加入饮料中。因此，该提案的目标是开发一种生产PPH的中试工厂放大方法，并确定含有PPH的饮料配方的最佳水平。中试工厂的扩大将通过合同在最重要的工业设施之一进行，每一步都经过优化，以生产公斤数量的产品。含有不同水平PPH的饮料(橙汁和苹果汁)配方将使用人体感官测试板和电子舌仪进行苦味测试。与现有的抗高血压药物和天然产品相比，PPH是独一无二的，因为它能够降低肾素活性并导致血压下降。目前，只有一个

Our previous work has isolated a bioactive pea protein hydrolysate (PPH) from the seeds of Canadian-grown yellow field peas. Oral administration to spontaneously hypertensive rats and human subjects reduced systolic blood pressure by up to 20 and 10 mmHg, respectively. Based on the animal and human studies we have concluded that the PPH is potential therapeutic agent against hypertension. In order to advance the PPH towards successful commercialization, we need to prove that it can be produced on large-scale suitable for technology transfer to the industry. Also, due to the potential bitter flavour of food protein hydrolysates, we must show that incorporation of the product into beverages can be optimized without reducing efficacy or potency of the product. Therefore, the objectives of the proposal are to develop a pilot plant scale-up method for producing PPH and to deetermine optimal levels of beverage formulations containing the PPH. Pilot plant scale-up will be performed by contract in one of the foremost industrial facilities with every step optimized for producing kilogram quantities of the product. Beverage (orange and apple juices) formulations that contain PPH at various levels will be tested for bitterness using a human sensory test panel in addition to an electronic tongue instrument. The PPH is unique when compared to existing antihypertensive drugs and natural products because of its ability to reduce activity of renin and cause reduction in blood pressure. Currently, only one